个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Clinical outcomes of coronavirus disease 2019 (COVID-19) in cancer patients with prior exposure to immune checkpoint inhibitors

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Wu, Qiuji[1,2,3] * ; Chu, Qian[4] ; Zhang, Hongyan[1,2,3] ; Yang, Bin[5] ; He, Xudong[6] ; Zhong, Yahua[1,2,3] ; Yuan, Xianglin[4] ; Chua, Melvin L. K.[1,7,8,9] ; Xie, Conghua[1,2,3] ;
单位： [1]Wuhan Univ, Dept Radiat & Med Oncol, Zhongnan Hosp, 169 Donghu Rd, Wuhan 430071, Hubei, Peoples R China [2]Wuhan Univ, Hubei Key Lab Tumor Biol Behav, Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China [3]Wuhan Univ, Hubei Canc Clin Study Ctr, Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China [4]Huazhong Univ Sci & Technol, Tongji Hosp, Dept Oncol, Tongji Med Coll, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China [5]Huazhong Univ Sci & Technol, Hubei Canc Hosp, Dept Med Oncol, Tongji Med Coll, Wuhan 430079, Hubei, Peoples R China [6]Hubei Univ Med, Dongfeng Hosp, Dept Gastroenterol, Shiyan 442000, Hubei, Peoples R China [7]Natl Canc Ctr Singapore, Div Radiat Oncol, 11 Hosp Crescent, Singapore 169610, Singapore [8]Natl Canc Ctr Singapore, Div Med Sci, Singapore 169610, Singapore [9]Duke NUS Med Sch, Oncol Acad Programme, Singapore 169857, Singapore
出处：
DOI： 10.1002/cac2.12077
ISSN：
基金：
National Medical Research Council Clinician-scientist award [NMRC/CSA/0027/2018]; Health Commission of Hubei Province Scientific Research Project [WJ2019H002]; Health Commission of Hubei Province Medical Leading Talent Project; Fundamental Research Funds for the Central Universities [2042018kf1037, 2042019kf0329]; Medical Science Advancement Program (Basic Medical Sciences) of Wuhan University [TFJC2018005]; Zhongnan Hospital of Wuhan University Science, Technology and Innovation Seed Fund [znpy2017049, znpy2018070]
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2019]版：
大类 | 2 区 医学
小类 | 3 区 肿瘤学
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区：
出版当年[2018]版：
Q4 ONCOLOGY
最新[2024]版：
Q1 ONCOLOGY

影响因子： 最新[2024版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者：
第一作者单位： [1]Wuhan Univ, Dept Radiat & Med Oncol, Zhongnan Hosp, 169 Donghu Rd, Wuhan 430071, Hubei, Peoples R China [2]Wuhan Univ, Hubei Key Lab Tumor Biol Behav, Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China [3]Wuhan Univ, Hubei Canc Clin Study Ctr, Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China
通讯作者：
通讯机构： [1]Wuhan Univ, Dept Radiat & Med Oncol, Zhongnan Hosp, 169 Donghu Rd, Wuhan 430071, Hubei, Peoples R China [2]Wuhan Univ, Hubei Key Lab Tumor Biol Behav, Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China [3]Wuhan Univ, Hubei Canc Clin Study Ctr, Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China [7]Natl Canc Ctr Singapore, Div Radiat Oncol, 11 Hosp Crescent, Singapore 169610, Singapore [8]Natl Canc Ctr Singapore, Div Med Sci, Singapore 169610, Singapore [9]Duke NUS Med Sch, Oncol Acad Programme, Singapore 169857, Singapore
推荐引用方式(GB/T 7714)：
Wu Qiuji,Chu Qian,Zhang Hongyan,et al.Clinical outcomes of coronavirus disease 2019 (COVID-19) in cancer patients with prior exposure to immune checkpoint inhibitors[J].CANCER COMMUNICATIONS.2020,40(8):374-379.doi:10.1002/cac2.12077.
APA：
Wu, Qiuji,Chu, Qian,Zhang, Hongyan,Yang, Bin,He, Xudong...&Xie, Conghua.(2020).Clinical outcomes of coronavirus disease 2019 (COVID-19) in cancer patients with prior exposure to immune checkpoint inhibitors.CANCER COMMUNICATIONS,40,(8)
MLA：
Wu, Qiuji,et al."Clinical outcomes of coronavirus disease 2019 (COVID-19) in cancer patients with prior exposure to immune checkpoint inhibitors".CANCER COMMUNICATIONS 40..8(2020):374-379

资源点击量：811 今日访问量：0 总访问量：560 更新日期：2025-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）